• Understanding Cancer’s Home

    Jan 19 | Diagnostics World News | Cancer tries its hardest not to be found. Seeking to better understand the early tumor micro-environment may prove to be a powerful harbinger of early cancer development. In our quest for early cancer detection, we should look more closely at the complex and potentially detectable changes in the micro-environment surrounding the tumor. More
  • Antibody Detection in Seconds, AI Screening Tool Launches, Racial Inequalities in Testing: COVID-19 Updates

    Jan 15 | Diagnostics World News I Princeton University spin-off launches AI COVID screening tool, new antibody test helps select donor blood samples for therapeutic use, concerns raised over UK’s rollout of rapid asymptomatic testing, and Wuhan study finds symptoms linger for many. Plus: FDA grants EUA for high-volume antigen test and asymptomatic testing, new simplified COVID-19 testing method, and nanomaterial-based biosensing platform detects COVID-19 antibodies in seconds. More
  • Diagnostics Outlook Bright Says Illumina At JP Morgan Healthcare Conference

    Jan 12 | Diagnostics World News | At the 39th Annual J.P. Morgan Healthcare Conference in San Francisco today, Illumina CEO Francis deSouza outlined Illumina’s take on the genomics market, focusing heavily on a rosy outlook for clinical genomics. More
  • Valencell Announces Cuffless Blood Pressure Monitoring For Finger, Wrist

    Jan 12 | Diagnostics World News | Valencell today announced that its calibration-free, cuffless blood pressure (BP) technology for wearables is now able to be used in devices worn on the finger and wrist including smartwatches, fitness bands, patches and pulse oximeter finger clips. More
  • Electricity-Producing Bacteria Power Test Of Antibiotic Effectiveness

    Jan 11 | Diagnostics World News | Energy-generating bacteria, only in recent years leveraged to power biobatteries, have now been deployed for paper-based biosensing of antibiotic effectiveness. The innovative twist here is a high-throughput antimicrobial susceptibility testing device that eliminates the need for lab culturing and provides actionable results within five hours. More
  • New Test Delivers Results in Minutes, Loss of Smell Common in Mild Cases, Entire UK Population To Be Home-Tested: COVID-19 Updates

    Jan 08 | Diagnostics World News I New technology has the potential for at-home immunity monitoring, novel COVID-19 test delivers results in under five minutes, Spectrum Solutions to provide saliva collection device for UK population weekly testing. Plus: Phillips, BioIntelliSense, University of Colorado receive award to validate BioSticker wearable sensor to detect early COVID-19 symptoms. More
  • Trendspotting: Top Diagnostics Issues In 2021

    Jan 07 | Diagnostics World News | Within the Diagnostics World vendor community, leaders have been working hard to synthesize what 2020 brought us and apply those learnings to 2021. Here are the full trends and predictions including pathogen surveillance, AMR, telehealth and home diagnostics, machine learning-based triage, omics for diagnostics, and supply chain reliability. More
  • All-In-One Metagenomic Test Quickly Identifies Pathogens From Multiple Sample Types

    Jan 06 | Diagnostics World News | An all-in-one metagenomics test developed by University of California San Francisco (UCSF) scientists could transform the way infectious diseases are diagnosed at the point of care, irrespective of the sample type. The same technology is being adapted as a means to simultaneously detect SARS-CoV-2 and track down drivers of COVID-19 outbreaks at the community level. More
  • AI-Assisted Breast Cancer Dx, Whole Genome Sequencing, Kidney Disease Dx, More

    Jan 04 | Diagnostics World News | Updates from Ibex Medical Analytics and Paige on AI-assisted breast cancer diagnoses, using vocal biomarkers to diagnose pulmonary hypertension, whole genome sequencing in diagnoses, and more. More
  • Top Stories of 2020: Regulatory Landscape, Emergency Use Authorization, Organs-On-A-Chip. And COVID-19

    Dec 29 | Diagnostics World News | By March, the whole world was faced with a massive diagnostics problem, and companies everywhere pivoted to focus on methods for diagnosing SARS-CoV-2 infections quickly, accurately, and with a test that could scale. But COVID-19 diagnoses weren’t the year’s only developments. We also covered the growing trends in medical monitoring, organ-on-a-chip models, the regulatory environment for laboratory-developed tests and much more. More
View more articles

 
DXX-Industry-spotlight

Acrobiosystems

Antigens & Antibodies for SARS-CoV-2 Diagnostic Kit Development

ACROBiosystems team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of high-quality antigen and antibody reagents to support the development of the diagnostic kits. The products include the high quality S trimer, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity tested on several platforms.

Click to learn more about ACRO’s hot matched antibody pairs and antigens.

DXX-Industry-spotlight

2020 Global Coronavirus Diagnostics Market


The report presents a detailed analysis of the Coronavirus diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Coronavirus definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: Hospitals, Commercial/Private Labs, Physician Offices and Public Health Labs.

Global Molecular Diagnostics Partnering 2014-2019: Deal trends, players, financials and forecasts


The report takes the reader through a comprehensive review Molecular Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Molecular Diagnostics partnering deals. The report presents financial deal term values for Molecular Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyze and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the Molecular Diagnostics partnering field; both the leading deal values and most active Molecular Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic deal making market.